The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 03, 2025 for Aayush Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Midcap 150 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aayush Agrawal, trustee of Aayush Agrawal Trust and a promoter of Ajanta Pharma Ltd, has created a fresh pledge on 4,65,000 shares (0.37% of total share capital) on March 28, 2025. The reason given for the pledge is a change in lender, with Jio Finance Ltd being the new financing institution. After this event, the trust's total encumbered shares stand at 52,30,002 (4.19% of share capital), up from 47,65,002 (3.81%) earlier. Aayush Agrawal Trust's overall promoter holding in the company remains 1,41,12,924 shares (11.30%). The disclosure was filed under SEBI (SAST) Regulation 31(1) and 31(2).
This is essentially a refinancing move by the promoter — switching the lender for pledged shares with a small increase in pledged quantity. It is a routine disclosure and does not indicate any sale, invocation, or reduction in promoter stake, so the direct impact on shareholders is minimal.